파트너십

"Calla Lily Clinical Care 및 모기업은 영국 정부의 혁신 부처인 Innoate UK의 큰 지원을 받았습니다. 2021년에 Innoate UK는 당사의 연구 개발 노력을 강화하기 위한 추가적인 자금 지원을 확정했습니다."

CLCC has designed an in-woman trial of our device with progesterone, working closely with the Clinical Trials Unit from University Hospitals Coventry & Warwickshire (UHCW). This is led by Professor Siobhan Quenby, our clinical co-lead and one of the world’s foremost authorities on miscarriage and preterm birth prevention. Siobhan led the highly-cited Lancet series (2021) on miscarriage and was co-applicant, major recruiter to and co-author on the two largest and most significant trials of vaginal progesterone to prevent miscarriage (PROMISE and PRISM). The results of these trials led to the UK’s NICE updating its miscarriage guideline, to now recommend women at high risk of miscarriage to take vaginal progesterone twice daily for up to 80 days – guidance that has subsequently been adopted in Australia and we believe is being closely followed in other countries, with potential to further expand the market opportunity for this indication